Strategy-Driven Innovation Consulting
In the Life Sciences
The 360Health Advising Model
Bridging Discovery and Delivery
-
360HealthStrategies LLC is a strategic consulting firm that specializes in transforming promising biomedical innovations into investable, fundable, and partner-ready assets.
-
We provide high-impact advisory services to academic institutions, early-stage biotech companies, and investors working at the forefront of translational science and innovation.
-
Our model leverages deep experience in academic medicine, biotech leadership, and commercialization strategy to provide a comprehensive 360° view of opportunities, risks, and value in the health innovation ecosystem.
Sector-Specific Expertise
Customized Solutions
Impactful Innovation
Sustainable Strategies
360Health Strategies
Accountable Advising at the Intersection of Innovation and Impact
360Health Strategies was founded by Dr. Johannes Vieweg, MD, a healthcare executive with deep experience in academic medicine, translational science, and biotechnology.​
He and his partners combine scientific rigor with strategic insight to ensure accelerated advancement of properly vetted discoveries into the biotech sector.
We act as a strategic partner, offering a rare blend of scientific fluency, business acumen, and real-world operational experience.
​
Differentiators
-
Founded by a physician-scientist and academic leader with deep insight into discovery and clinical implementation
-
Multidimensional approach blending science, policy, commercialization, and leadership
-
Trusted partner to universities, VCs, accelerators, and emerging biotechs
Dr. Johannes Vieweg, MD,
Founder and Principal Advisor, 360Health Strategies LLC
Our Clients
-
ACADEMIC INSTITUTIONS with underleveraged translational portfolios
-
UNIVERSITY INNOVATION OFFICES & academic teams
-
VENTURE AND CORPORATE INVESTORS conducting technical due diligence
-
First-time FOUNDERS or STARTUPS seeking strategic clarity and investor readiness
-
ACCELERATORS and INCUBATORS supporting biotech innovation
-
​PHARMACEUTICAL COMPANIES evaluating external innovation partnerships
A Broken Path to Market​
Despite significant public and private investments, the number of new U.S. biotech drugs reaching the market each year remains at historic lows. A substantial portion of promising biotech innovations never reach patients, often lost in the transition from academic discovery to clinical trial readiness. This phase is now widely recognized as the most critical—and under-resourced—obstacle in drug development.
Core Services and Value Proposition
End-to-End Consulting for Translational Success
Our Services
Innovation Scouting and Due Diligence
Evaluate scientific potential, market fit, and IP positioning
Translational Strategy & Roadmapping
Build development plans from preclinical to clinical stages
Licensing & IP Advisory
Navigate term sheets, valuations, and tech transfer partnerships
Exit & Commercialization Planning
Clarify product value, regulatory path, and go-to-market strategy
A Changing Investment Paradigm
Strengthening U.S. Academic Science Leadership Amid Global Competition
An increasing number of investors and biotech ventures are embracing greater support for U.S. scientific leadership, especially amid global competition and shrinking public funding.
Investments are focused on building academic-private discovery pipelines and support for
earlier-stage science leading to breakthrough academic tech.
Investments to be structured as direct investments into early-stage companies or in-licensed patents and technologies
Importantly, today's investors are seeking more comprehensive support and look for greater input in facilitating the translational pathway
We offer assistance ranging from technology evaluations, IP acquisition & licensing to
internal incubation and subsequent spin-out into new companies or outlicensed to Pharma for fees, milestone payments and royalties.
​
Featured Appearances and Events
